The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

Basit Öğe Kaydı
dc.contributor.authorAkgul, Fethiye
dc.contributor.authorArslan, Yusuf
dc.contributor.authorCelik, Mehmet
dc.contributor.authorKarasahin, Omer
dc.contributor.authorCelen, Mustafa Kemal
dc.date.accessioned2024-04-24T17:28:03Z
dc.date.available2024-04-24T17:28:03Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Chronic hepatitis B (CHB) patients who are under the treatment of antiviral agents should be monitored in routine control visits. However, during the COVID-19 pandemic, the visits were interrupted. Objectives: This study aimed to investigate whether these patients were affected regarding clinical, laboratory, and treatment outcomes. Methods: This prospective study consisted of CHB patients aged > 18 who were applied to 3 tertiary centers between 14 February and 30 March 2022. The patients were selected from the ones who regularly applied to outpatient clinics and under the treatment of antiviral agents before the pandemic. The demographic and laboratory values, including serologic, biochemistry, and molecular results, were compared between the 2 groups who came and did not come to control visits. Results: A total number of 220 patients were included. More than half (n = 142, 64.5%) were female. The median age was 44 years (19 - 73). A hundred and forty-two (64.5%) patients did not come to control visits during the pandemic. The most common reason was anxiety about COVID-19. The tenofovir treatment was replaced with entecavir (ETV) due to osteopenia and with alafenamide due to osteopenia and/or renal failure. The previous agents were re-started in 27 (79.5%) patients who discontinued the treatment. Conclusions: The COVID-19 pandemic negatively impacted the follow-up of CHB patients. In this regard, 15.5% of patients stopped their treatments. The patients who stopped their follow-ups and continued tenofovir disoproxil fumarate (TDF) had proteinuria and decreases in bone mineral density (BMD) and estimated glomerular filtration rate (eGFR) levels.en_US
dc.identifier.doi10.5812/hepatmon-132174
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85145507786
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.5812/hepatmon-132174
dc.identifier.urihttps://hdl.handle.net/11468/20309
dc.identifier.volume22en_US
dc.identifier.wosWOS:001147599200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherBrieflanden_US
dc.relation.ispartofHepatitis Monthly
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19en_US
dc.subjectPandemicen_US
dc.subjectChronic Viral Hepatitis Ben_US
dc.subjectTenofovir Disoproxilen_US
dc.subjectBone Mineral Densityen_US
dc.subjectGlomerular Filtration Rateen_US
dc.titleThe Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Studyen_US
dc.titleThe Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu